ER, PR, AND HER2
STATUS EXPLAINED
Your breast cancer biopsy report includes ER, PR, and HER2 status — three biomarkers that determine which treatments your cancer will respond to, guide adjuvant therapy choices, and predict prognosis. Understanding what they mean transforms an intimidating pathology report into a clear treatment roadmap.
analyticsAt a Glance
- check_circleER-positive (ER+): cancer cells have oestrogen receptors — hormone therapy (tamoxifen, AIs) is effective; 70–75% of breast cancers
- check_circlePR-positive (PR+): progesterone receptor expression — usually accompanies ER+; further confirms hormone sensitivity
- check_circleHER2-positive (HER2+): HER2 protein overexpression — targeted anti-HER2 therapy (trastuzumab, pertuzumab) is effective; 15–20% of cases
- check_circleTriple-negative (TNBC): no ER, PR, or HER2 expression — chemotherapy and immunotherapy are the primary options; 15% of cases
What Are Hormone Receptors and Why Do They Matter in Breast Cancer?
Every breast cancer cell has a set of proteins on its surface and inside its nucleus — some of which act as receptors for hormones and growth factors. When oestrogen binds to an oestrogen receptor (ER) inside a breast cancer cell, it triggers the cell to divide. When HER2 protein — a growth factor receptor on the cell surface — is over-expressed, it drives rapid, aggressive cell proliferation independently of hormones.
“Your receptor status does not just describe your tumour — it defines your treatment. A pathology report that identifies ER+, HER2- disease has just told you that hormone therapy will work and that HER2-targeted drugs will not. That is a treatment plan encoded in four letters.”
How Receptor Testing Is Performed
Immunohistochemistry (IHC) is the standard test — antibodies that bind specifically to ER, PR, or HER2 are applied to thin sections of the tumour biopsy. A pathologist reads the proportion of cells staining positive and the intensity of staining. HER2 overexpression that is equivocal (IHC 2+) is confirmed by fluorescence in situ hybridisation (FISH), which counts HER2 gene copies.
Discordance: When Results from Different Sites Differ
In 15–20% of patients, receptor status differs between the primary tumour and a biopsy of a metastatic site. HER2 in particular can change from positive to negative (or vice versa) at metastasis. Rebiopsy of a new metastatic lesion before starting treatment for advanced disease is a critical step — treating HER2-negative metastasis with trastuzumab is ineffective, and missing a new HER2-positive site means missing a targeted therapy option.
Breast Cancer Subtypes by Receptor Status: A Complete Reference
Receptor status defines five clinically distinct breast cancer subtypes — each with different biology, prognosis, and treatment approach.
| Subtype | Receptor Profile | Frequency | Key Treatments | Prognosis Note |
|---|---|---|---|---|
| Luminal A | ER+/PR+ (high), HER2−, Ki67 low | 40–50% | Endocrine therapy alone (5–10 yr); CDK4/6 inhibitor if high risk | Best prognosis; lowest recurrence with adequate endocrine therapy |
| Luminal B (HER2−) | ER+, HER2−, Ki67 high OR PR low | 20% | Endocrine therapy + chemotherapy (if high Oncotype/Mammaprint); CDK4/6 inhibitor in advanced disease | Intermediate prognosis; higher proliferation drives recurrence risk |
| Luminal B (HER2+) | ER+/PR+, HER2+ | 10% | Endocrine therapy + HER2-targeted agents (trastuzumab, pertuzumab) + chemotherapy | Worse than Luminal A; HER2 therapy substantially improves outcomes |
| HER2-enriched | ER−/PR−, HER2+ | 5–10% | HER2-targeted agents (trastuzumab, pertuzumab, T-DM1, T-DXd) + chemotherapy; no endocrine therapy | Aggressive but highly treatable with anti-HER2 therapy |
| Triple-Negative (TNBC) | ER−/PR−, HER2− | 15–20% | Chemotherapy; immunotherapy (pembrolizumab for high-risk/PD-L1+); PARP inhibitors if BRCA-mutant; sacituzumab govitecan | Highest recurrence risk in first 3–5 years; no endocrine or HER2 options |
How to Read Your Pathology Report: ER, PR, and HER2 Results Decoded
Pathology reports use standardised scoring systems — but the language can be confusing. Here is how to interpret each result.
Oestrogen Receptor (ER) Result
ER status is reported as positive or negative, with a percentage of cells staining positive and an Allred score (0–8). ER-positive is defined as ≥1% of cells staining positive on IHC — a very low threshold. Allred score ≥3 is ER-positive. A result of 'ER+, 90% cells, Allred 8' indicates strong receptor expression and high hormone sensitivity. 'ER+, 2% cells, Allred 3' is technically positive but with weaker hormone sensitivity — your oncologist will discuss whether full endocrine therapy is warranted in this borderline case.
Progesterone Receptor (PR) Result
PR is reported similarly to ER — as a percentage of positive cells. PR positivity generally accompanies ER positivity and further confirms hormone sensitivity. ER+/PR+ tumours tend to have better hormone therapy responses than ER+/PR− tumours. PR− with ER+ is a signal of higher proliferative activity and may prompt consideration of chemotherapy alongside endocrine therapy. A truly ER−/PR+ tumour is rare and may represent a technical error — repeat testing is recommended.
HER2 Result: IHC Score and FISH
HER2 IHC is reported as 0, 1+, 2+, or 3+. Score 0 and 1+ are HER2-negative. Score 3+ is HER2-positive (protein overexpression). Score 2+ is equivocal — FISH testing is performed to count HER2 gene copies. FISH ratio ≥2.0 (HER2 copies/chromosome 17) confirms HER2 amplification and positivity. The recent HER2-low designation (IHC 1+ or IHC 2+/FISH-negative) identifies patients eligible for trastuzumab deruxtecan (T-DXd, Enhertu) — an important new category that most patients are not told about without specialist review.
Key Numbers: Receptor Status in Breast Cancer
Frequency and clinical significance figures for the major receptor profiles.
- 70–75%Of breast cancers are ER-positiveThe majority of breast cancers express oestrogen receptors — making endocrine therapy relevant to more patients than any other breast cancer systemic treatment.
- 15–20%Of breast cancers are HER2-positiveHER2 overexpression (IHC 3+ or FISH-amplified) defines a subgroup for which trastuzumab and other HER2-targeted agents have dramatically improved outcomes.
- ~55%Of breast cancers are HER2-low (IHC 1+ or 2+/FISH-)The newly recognised HER2-low category — eligible for T-DXd (trastuzumab deruxtecan) — significantly expands the HER2-targeted treatment population.
- 15–20%Receptor discordance rate between primary and metastasisHighlights why rebiopsy of a new metastatic site before starting treatment for advanced disease is a clinical standard, not optional.
ER-Positive vs Triple-Negative: Two Very Different Diseases
ER-positive and triple-negative breast cancer have profoundly different biology, treatment options, and long-term risk profiles — illustrating why receptor status is the most important piece of information in the pathology report.
ER-Positive (Luminal) Breast Cancer
- Long-term endocrine therapy controls recurrence risk5–10 years of tamoxifen or aromatase inhibitor reduces recurrence risk by 30–50% and continues to provide benefit even after treatment stops — the 'carry-over' effect.
- Low recurrence risk in years 5–20 with adequate therapyER+ breast cancer can recur late — beyond 5 years and even beyond 10 years. Extended adjuvant endocrine therapy addresses this late recurrence pattern.
- CDK4/6 inhibitors have transformed metastatic prognosisPalbociclib, ribociclib, and abemaciclib added to endocrine therapy have more than doubled progression-free survival in metastatic ER+/HER2− breast cancer.
- Generally slower progression than TNBCLuminal breast cancer tends to grow more slowly and metastasise later — allowing longer treatment windows and better quality of life in the advanced setting.
Triple-Negative Breast Cancer (TNBC)
- No hormone receptor or HER2 target availableTNBC lacks all three therapeutic targets — treatment relies on chemotherapy, immunotherapy (pembrolizumab if PD-L1+), and PARP inhibitors if BRCA-mutant.
- Higher recurrence risk in years 0–5TNBC has the highest recurrence risk in the first 3–5 years after diagnosis — after 5 years, the risk of recurrence falls sharply.
- BRCA status is critically important in TNBCBRCA1 and BRCA2 mutations are found in 15–20% of TNBC patients — enabling access to PARP inhibitors (olaparib, talazoparib) as targeted therapy.
- Immunotherapy (pembrolizumab) active in high-risk TNBCPembrolizumab added to neoadjuvant chemotherapy and continued as adjuvant therapy significantly improves pCR and EFS in stage II–III TNBC.
More from the Hormone Therapy Resource Library
Continue exploring breast cancer biomarkers and treatment options.
- What Is Hormone Therapy for Cancer and How Does It Work?
- Tamoxifen: Side Effects, CYP2D6 Interactions, and Monitoring
- Aromatase Inhibitors: Letrozole, Anastrozole, and Exemestane
- Ovarian Suppression for Breast Cancer: Goserelin and Oophorectomy
- Hormone Therapy for Breast Cancer — Complete Guide
- CDK4/6 Inhibitors in Breast Cancer
Frequently Asked Questions
Common questions about receptor status and what the results mean for treatment.
About ER, PR, and HER2
My report says ER+, 5% — is this really hormone-sensitive enough to justify 10 years of tamoxifen?
This is a genuinely nuanced situation. The current ASCO/CAP guideline defines ER-positive as ≥1% of cells staining positive, which means a 5% ER result is technically positive and endocrine therapy is recommended. However, tumours with 1–10% ER expression ('ER-low positive') may behave more like triple-negative breast cancer — particularly if PR is also negative and Ki67 is high. Recent data suggest the benefit of endocrine therapy is less clear in this 1–10% ER range. This is an area where specialist oncology review and consideration of gene expression profiling (Oncotype DX, Prosigna) adds value in determining whether chemotherapy should accompany endocrine therapy.
What is HER2-low and why does it matter?
HER2-low is a new category defined as IHC 1+ or IHC 2+ with negative FISH — previously considered HER2-negative and ineligible for anti-HER2 therapy. The DESTINY-Breast04 trial demonstrated that trastuzumab deruxtecan (T-DXd, Enhertu) has significant activity in HER2-low metastatic breast cancer — improving overall survival compared to chemotherapy. Approximately 55% of all breast cancers are HER2-low, including many ER-positive tumours that were previously considered to have no HER2 target. Patients with metastatic ER+/HER2-low disease who have progressed on endocrine therapy should ask their oncologist whether T-DXd is appropriate for their next treatment line.
Should I retest my tumour if I was diagnosed more than 5 years ago?
If your original biopsy results are available and the diagnosis was made at a pathology laboratory with standard IHC quality controls, retesting the primary tumour is generally not needed. However, if you are now developing metastatic disease, rebiopsy of a new metastatic site is strongly recommended — receptor status can change (discordance) in 15–20% of cases between primary and metastatic tumour, and this changes the treatment plan. A metastasis that tests HER2-positive when the primary was HER2-negative opens access to trastuzumab and pertuzumab. A liver or bone biopsy of a new metastasis is a brief outpatient procedure that substantially changes the information base for treatment decisions.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want a Second Opinion on Your Receptor Status and Treatment Plan?
CancerFax can arrange a specialist breast oncology second opinion on your pathology report and receptor status — particularly for borderline or discordant results — and connect you with oncologists in China and India experienced in all breast cancer subtypes.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.